Hyperice v. Therabody: Patent Infringement Battle Over Percussive Therapy Devices
Hyper Ice, Inc. and Hyperice IP Subco, LLC filed suit against rival Therabody, Inc. in the Central District of California, asserting US11857482B1 against eight Theragun and TheraFace products. The case was administratively closed after 119 days when the court consolidated it into a broader multi-case cluster ahead of a Markman claim construction hearing.
Hyperice targets Therabody’s full product lineup in percussion therapy IP fight
On February 23, 2024, Hyper Ice, Inc. and its IP holding entity Hyperice IP Subco, LLC filed a patent infringement complaint against Therabody, Inc. in the Central District of California (Case No. 8:24-cv-00390). The action asserts US11857482B1, a patent directed to percussive and LED-based therapy device technology, against eight of Therabody’s flagship consumer wellness products — including the Theragun PRO, Elite, Mini, Prime, Relief, and Sense, as well as the TheraFace PRO and TheraFace LED.
The case did not proceed to substantive adjudication on its own trajectory. On June 21, 2024 — 119 days after filing — the court issued an order consolidating this case, along with four related actions, into lead Case No. 8:24-cv-00098-JWH-DFM for pretrial purposes through the Markman hearing. The clerk was directed to administratively close Case No. 8:24-cv-00390. Consolidation is a procedural mechanism, not a merits ruling; the underlying infringement claims remain live within the lead consolidated proceeding.
The speed of consolidation — under four months from filing — suggests the court identified significant overlap across the related Hyperice actions and moved proactively to streamline claim construction. The breadth of accused products across both percussive and LED facial therapy categories, combined with the multi-case filing strategy, is consistent with an aggressive IP enforcement campaign by Hyperice against Therabody across its core consumer product portfolio. The merits of the ‘482 patent claims remain unresolved in the public record at this stage.
Filing to Case Consolidated in 119 days
119 days — administratively closed at consolidation order, ahead of Markman hearing
Case consolidated: what the administrative closure means for both parties
Consolidation ≠ dismissal — the claims survive
Administrative closure upon consolidation under Fed. R. Civ. P. 42(a) is a docket management tool, not a termination of claims. The court merged this case with four related Hyperice v. Therabody actions into lead Case No. 8:24-cv-00098 to coordinate pretrial proceedings through the Markman hearing. All infringement allegations asserted in this case travel forward within the consolidated proceeding.
No merits ruling issuedHyperice retains full enforcement rights under the ‘482 patent
Consolidation does not prejudice Hyperice’s infringement claims. The company continues to pursue relief against Therabody’s Theragun and TheraFace lines within the lead action. A coordinated multi-case strategy may give Hyperice leverage in claim construction by presenting consistent claim scope arguments across all consolidated matters simultaneously.
Claims active in lead caseTherabody faces coordinated claim construction across all Hyperice suits
Consolidation concentrates litigation risk for Therabody: a single adverse Markman ruling on key claim terms could affect all consolidated cases at once. With O’Melveny & Myers fielding a six-attorney team, Therabody appears prepared for substantive engagement, but the unified pre-trial schedule reduces opportunities to manage cases independently.
Shared Markman exposurePercussive therapy IP war signals sector-wide enforcement escalation
The simultaneous multi-case filing across five related actions suggests Hyperice is pursuing a broad exclusionary strategy against Therabody’s core product portfolio. For other players in the consumer percussive and LED therapy device space, this consolidation pattern — with a Markman hearing as the pivotal moment — is consistent with a litigation posture designed to force licensing or design-arounds before trial.
Watch the Markman rulingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Hyper Ice, Inc. | Company | Consumer wellness device company and IP holding subsidiary — holder of US11857482B1Search in Eureka ↗ |
| Co-Plaintiff | Hyperice IP Subco, LLC | Company | Search in Eureka ↗ |
| Defendant | Therabody, Inc. | Company | Therabody, Inc. — maker of Theragun percussive therapy and TheraFace LED devicesSearch in Eureka ↗ |
| Plaintiff counsel | Benjamin A. Herbert | Attorney | Counsel for Hyper Ice, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lawrence Robert LaPorte | Attorney | Counsel for Hyper Ice, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Lewis Brisbois Bisgaard & Smith LLP | Law Firm | Representing Hyper Ice, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Miller Barondess, LLP | Law Firm | Representing Hyper Ice, Inc.Search in Eureka ↗ |
| Defendant counsel | Brett J. Williamson | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Cameron W. Westin | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Gyuhyun Bae | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Jaston P. Burri | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Laura Bayne Gore | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Marc J. Pensabene | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant law firm | O’melveney & Myers LLP | Law Firm | Representing Therabody, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Central District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a purely procedural disposition: this case was administratively closed solely to consolidate pretrial management with four related Hyperice v. Therabody actions. No claim construction, infringement finding, or validity ruling was issued. The order’s direction to ‘close the following case administratively’ does not resolve or prejudice any substantive rights — the ‘482 patent infringement allegations against the eight named Therabody products remain pending within the consolidated lead action and await Markman determination.
US11857482B1 — Percussive and LED Therapy Device Technology
US11857482B1, filed under application number US17/681367, is asserted by Hyperice IP Subco, LLC as covering technology central to percussive and LED-based therapy devices. The patent’s issuance as a B1 grant — indicating no prior publication before grant — is consistent with a continuation or fast-tracked prosecution pathway. The technology domain spans motorised percussive massage devices and LED-integrated facial treatment tools, both of which sit at the core of the high-growth consumer wellness device market.
Strategically, the ‘482 patent’s assertion against eight distinct Therabody products across two product lines suggests it contains claims broad enough to reach varied device configurations. In a sector where Hyperice and Therabody are the two dominant players, ownership of foundational patents covering percussive actuation or integrated LED therapy protocols represents a significant competitive moat. Competitors and new entrants in the percussive therapy, sports recovery, and consumer photobiomodulation device space should treat this patent as a high-priority monitoring and FTO target.
Should your product team run an FTO against US11857482B1?
Any company designing or commercialising percussive massage devices, handheld therapy guns, or LED-based facial treatment tools — particularly integrated multi-modality wellness devices — should conduct a freedom-to-operate analysis against US11857482B1. The breadth of Therabody’s accused product range (from entry-level Theragun Mini to the premium TheraFace PRO) suggests the patent may cover both hardware architecture and operational method claims applicable across price tiers and product categories.
PatSnap Eureka’s FTO Search Agent enables R&D and product teams to map claim language from US11857482B1 against your device specifications, flag prosecution history estoppel, and surface design-around prior art — all before claim construction locks in the operative scope. With the Markman hearing in the consolidated action still pending, this is the optimal window to assess and document your FTO position before judicial interpretation narrows or expands the claim boundaries.
Run a freedom-to-operate analysis on US11857482B1 to assess your product’s exposure
Run FTO in Eureka →Similar percussive therapy and consumer wellness device patent cases
Explore related patent infringement actions in the percussive therapy and consumer wellness device sector litigated in the Central District of California.
What this case signals for the percussive therapy device IP landscape
Hyperice’s five-case filing blitz against Therabody is reshaping IP enforcement norms in the fast-growing consumer wellness device sector.
Multi-case consolidation is the new playbook in consumer wellness IP
Filing five concurrent patent actions and allowing them to consolidate for Markman is an increasingly common aggressive enforcement strategy. It maximises pressure on the defendant while streamlining the plaintiff’s own litigation burden. Companies in percussive therapy, sports recovery, and LED wellness devices should anticipate this pattern from well-capitalised IP holders.
The Markman hearing is now the pivotal event for all parties
With five cases consolidated into a single claim construction proceeding, the outcome of the Markman hearing in Case No. 8:24-cv-00098 will effectively set the litigation trajectory for Therabody across its entire accused product line. Narrow claim construction favoring Therabody could collapse multiple cases simultaneously; broad construction amplifies Hyperice’s leverage.
Hyper v Therabody — key questions answered
The case was administratively closed on June 21, 2024, after the court consolidated it with four related Hyperice v. Therabody actions into lead Case No. 8:24-cv-00098-JWH-DFM for pretrial proceedings through the Markman hearing. The infringement claims under US11857482B1 were not dismissed and remain active in the consolidated proceeding.
Hyperice asserted US11857482B1 (application number US17/681367), a patent covering percussive and LED-based therapy device technology, against eight Therabody products including the Theragun PRO, Elite, Mini, Prime, Relief, Sense, TheraFace PRO, and TheraFace LED.
Consolidation under Fed. R. Civ. P. 42(a) is a procedural measure to coordinate related cases for pretrial efficiency. Administrative closure of this case does not terminate Hyperice’s infringement claims. All substantive proceedings, including claim construction and any trial, will proceed under the lead consolidated case number.
The complaint accused eight products: TheraFace LED, TheraFace PRO, Theragun Elite, Theragun Mini, Theragun PRO, Theragun Prime, Theragun Relief, and Theragun Sense — spanning both Therabody’s percussive massage and LED facial therapy product lines.
The Markman hearing will determine how the court construes the key claim terms of the patents at issue across all five consolidated cases. Given the number of accused products and cases, a ruling favoring broad claim scope would significantly amplify Hyperice’s infringement arguments, while narrow construction could weaken or collapse multiple claims simultaneously.
PatSnap Eureka searches patents and litigation data to answer instantly.